On immunohistochemical analyses, we confirmed the specificity of the antibodies used by immunoblotting using DCIS cells overexpressing E-cad, CAM5, and/or CAM6 as well as DCISCAF2cy expressing shRNAs against E-cad, CAM5, CAM6, or ZEB1. This evidence concerns the gene ZEB1 and ductal breast carcinoma in situ.